Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.73 |
| ▸ | RAB9A | P51151 | 5/20 | 0.73 |
| ▸ | PLK1 | P53350 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | CA1 | P00915 | 2/20 | 0.61 |
| ▸ | CA2 | P00918 | 2/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.58 |
| ▸ | RELA | Q04206 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16685001 | 0.93 | NPC1 (0.83) | NPC1RAB9APLK1SMN1; SMN2HPGD | |
| SCHEMBL20707159 | 0.89 | NPC1 (0.88) | NPC1RAB9APLK1SMN1; SMN2HPGD | |
| SCHEMBL14271589 | 0.84 | NPC1 (0.75) | NPC1RAB9APLK1SMN1; SMN2HPGD | |
| SCHEMBL9489987 | 0.84 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2HPGDCA1 | |
| SCHEMBL11756315 | 0.84 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2HPGDCA1 | |
| SCHEMBL11761105 | 0.84 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2HPGDCA1 | |
| SCHEMBL11758269 | 0.84 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2HPGDCA1 | |
| SCHEMBL11755990 | 0.84 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2HPGDCA1 | |
| SCHEMBL11754310 | 0.84 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2HPGDCA1 | |
| SCHEMBL6360344 | 0.84 | NPC1 (0.75) | NPC1RAB9APLK1SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110305770-A1 | RELEASABLE POLYMERIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEM | ENZON PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110305770-A1 | RELEASABLE POLYMERIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEM | KPNA6, LPAR6, KAT6B | NPC1 271/4885RAB9A 2128/4885PLK1 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.